GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Verseon Corp (LSE:VERS) » Definitions » LT-Debt-to-Total-Asset

Verseon (LSE:VERS) LT-Debt-to-Total-Asset : 0.47 (As of Jun. 2019)


View and export this data going back to 2015. Start your Free Trial

What is Verseon LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Verseon's long-term debt to total assests ratio for the quarter that ended in Jun. 2019 was 0.47.

Verseon's long-term debt to total assets ratio increased from Jun. 2018 (0.39) to Jun. 2019 (0.47). It may suggest that Verseon is progressively becoming more dependent on debt to grow their business.


Verseon LT-Debt-to-Total-Asset Historical Data

The historical data trend for Verseon's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Verseon LT-Debt-to-Total-Asset Chart

Verseon Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial 15.71 - - 0.05 0.47

Verseon Semi-Annual Data
Dec11 Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.05 0.39 0.47 0.47

Verseon LT-Debt-to-Total-Asset Calculation

Verseon's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2018 is calculated as

LT Debt to Total Assets (A: Dec. 2018 )=Long-Term Debt & Capital Lease Obligation (A: Dec. 2018 )/Total Assets (A: Dec. 2018 )
=20.891/44.524
=

Verseon's Long-Term Debt to Total Asset Ratio for the quarter that ended in Jun. 2019 is calculated as

LT Debt to Total Assets (Q: Jun. 2019 )=Long-Term Debt & Capital Lease Obligation (Q: Jun. 2019 )/Total Assets (Q: Jun. 2019 )
=21.462/45.459
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Verseon  (LSE:VERS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.


Verseon LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Verseon's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Verseon (LSE:VERS) Business Description

Traded in Other Exchanges
N/A
Address
47071 Bayside Parkway, Fremont, CA, USA, 94538
Verseon Corp is a part of the healthcare sector in the United States. It is a technology-based pharmaceutical company with a computer-driven drug discovery platform. The company designs novel drug candidates that are unlikely to be found using conventional methods. It is also engaged in drug discovery programs such as the diabetic macular edema product candidates, which treat the diseases by controlled disruption of the kallikrein kinin cascade.

Verseon (LSE:VERS) Headlines